Abstract
Mammalian sterile 20-like kinase 1 (Mst1) is a critical component of the Hippo signaling pathway, which regulates a variety of biological processes ranging from cell contact inhibition, organ size control, apoptosis and tumor suppression in mammals. Mst1 plays essential roles in the heart disease since its activation causes cardiomyocyte apoptosis and dilated cardiomyopathy. However, the mechanism underlying Mst1 activation in the heart remains unknown. In a yeast two-hybrid screen of a human heart cDNA library with Mst1 as bait, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was identified as an Mst1-interacting protein. The interaction of GAPDH with Mst1 was confirmed by co-immunoprecipitation in both co-transfected HEK293 cells and mouse heart homogenates, in which GAPDH interacted with the kinase domain of Mst1, whereas the C-terminal catalytic domain of GAPDH mediated its interaction with Mst1. Moreover, interaction of Mst1 with GAPDH caused a robust phosphorylation of GAPDH and markedly increased the Mst1 activity in cells. Chelerythrine, a potent inducer of apoptosis, substantially increased the nuclear translocation and interaction of GAPDH and Mst1 in cardiomyocytes. Overexpression of GAPDH significantly augmented the Mst1 mediated apoptosis, whereas knockdown of GAPDH markedly attenuated the Mst1 activation and cardiomyocyte apoptosis in response to either chelerythrine or hypoxia/reoxygenation. These findings reveal a novel function of GAPDH in Mst1 activation and cardiomyocyte apoptosis and suggest that disruption of GAPDH interaction with Mst1 may prevent apoptosis related heart diseases such as heart failure and ischemic heart disease.
Introduction
Mammalian sterile 20—like kinase 1 (Mst1) is an ubiquitously expressed serine/threonine kinase with a similarity to the Hippo kinase from Drosophila and it is a critical component of the Hippo signaling pathway, which regulates a variety of biological processes ranging from cell contact inhibition, cell growth, organ size control, apoptosis and tumor suppression in mammals [1], [2]. Human Mst1 has two caspase cleavage sites located between the catalytic and regulatory domains, which mediate the cleavage of the autoinhibitory domain [3], [4]. Intact Mst1 is localized predominantly in the cytoplasm, however, in response to a variety of apoptotic stimuli, Mst1 is cleaved by caspases to produce a 34–36-kDa N-terminal constitutively active fragment and this cleavage markedly increases Mst1 kinase activity and translocates the cleaved Mst1 to the nucleus where it phosphorylates histone H2B on Ser14, resulting in chromatin condensation, DNA fragmentation, and, ultimately, cell apoptosis [4]–[6]. In addition to Histone H2B, several Mst1 substrates, including FOXO [7]–[9], LATS1/2 [10], [11], JNK [12] and cardiac troponin I [13], have been recently identified. For instance, MST1 has been shown to phosphorylate FOXO and promote FOXO nuclear translocation, thereby inducing apoptosis in neuronal cells [7], [8].
Regulation of Mst1 appears to occur mainly at posttranslational levels. In addition to its activation by proteolytic cleavage, Mst1 autophosphorylation has been proposed to contribute to the kinase activation [14]. Several phosphorylation sites have been identified in Mst1, namely Thr175, Thr177, Thr183, Thr187, Ser327 and Thr387, of which, Thr183 and Thr187 appear to be essential for kinase activation [14]–[16]. In addition, protein-protein interactions have also been shown to play critical roles in the regulation of Mst1 activity. Thus far, several proteins including Ras association domain family protein (Rassf) [16]–[18], hWW45 [17], [19], PHLPP1 [20], and Heat Shock Protein 70 (Hsp70) [21], have been identified to interact with Mst1 and regulate Mst1 activation. For instance, RASSF family of tumor suppressors have been shown to interact with and stabilize Mst1, thereby preventing Mst1 for the degradation and inhibiting tumor growth [18], [22]. In contrast, our recent results demonstrated that Hsp70 decreases Mst1 activity through promoting Mst1 degradation via a CHIP dependent pathway, thereby preventing cancer cells from cisplatin induced apoptosis [21].
Recently, the physiological role of Mst1 in the cardiovascular system has begun to be explored. In cardiomyocytes, Mst1 is activated by pathological stimuli, such as hypoxia/reoxygenation in vitro and ischemia/reperfusion in vivo [23]. Cardiac-specific over-expression of Mst1 has been shown to cause dilated cardiomyopathy in mice [23]. Inhibition of endogenous Mst1 prevents apoptosis of cardiomyocytes and cardiac dysfunction after myocardial infarction without producing cardiac hypertrophy [23], [24]. Recently, we identified Mst1 as a novel kinase that mediates cTnI phosphorylation and plays a critical role in the modulation of myofilament function in the heart [13]. However, despite these important functions, little is relatively known about the mechanisms underlying the regulation of the Mst1 activation in the heart. In an attempt to identify novel cardiac proteins that may associate with Mst1 and regulate Mst1 activation in the heart, we performed yeast two-hybrid screen of a human heart cDNA library using the dominant negative form of Mst1 (K59R) as bait and subsequently, we identify glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a novel Mst1-interacting protein that positively regulates Mst1 activation and cell apoptosis in cardiomyocytes.
Materials and Methods
Cell culture
HEK293T and Ad293 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen) supplemented with 10% Fetal Bovine Serum (FBS) (Gibco) and were maintained at 37°C with 5% CO2. Cells were transiently transfected with FuGENE 6 (Roche Applied Science) using the manufacturer's protocol.
Yeast Two-Hybrid library screening and interaction assays
To identify novel proteins that interact with Mst1, we screened a human heart cDNA library using human dominant-negative Mst1 (K59R) as bait and the MATCHMAKER GAL4 yeast 2-hybrid system 3 (Clontech Laboratories Inc) as previously described [13], [21]. The screening was performed in AH109 yeast cells according to the protocol provided by the Clontech Matchmaker Two-Hybrid System. Positive colonies were subject to multiple rounds of additional selection in the appropriate medium and β-galactosidase (β-gal) filter assays to verify specificity.
Primary culture of neonatal rat ventricular myocytes (NRVMs) and hypoxia/reoxygenation injury
We obtained ventricles from 1-day-old Sprague-Dawley rats and isolated cardiac myocytes by digestion with trypsin-EDTA and type 2 collagenase as previously described [25]. Neonatal rats were obtained from Charles River Laboratories North Wilmington, Mass. This study was reviewed and approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University. Hypoxia was achieved by placing the cells in a hypoxia chamber filled with 5% CO2 and 95% N2 at 37°C for 12 hours. Following hypoxia exposure, cells were reoxygenated by placing cells in the normoxic culture medium for 24 hours 26]
Coimmunoprecipitation of Mst1 and GAPDH in HEK293T cells and cardiomyocytes
HEK293T cells were transiently transfected with Mst1 and GAPDH cDNAs using FuGENE 6 as described by the manufacturer (Roche Applied Science). Both HEK293T cells and cardiomyocytes were lysed in the buffer containing 1% Nonidet P-40, 150 mmol/L NaCl, 50 mmol/L Tris (pH 8), 100 µmol/L EDTA, and protease inhibitors. Coimmunoprecipitation of Mst1 and GAPDH was performed essentially as described [25]. The following antibodies were used for detection and immunoprecipitation: rabbit polyclonal c-Myc (Invitrogen), mouse monoclonal FLAG M2 (Sigma), mouse monoclonal GAPDH (Abcam), rabbit polyclonal GAPDH (Abcam), anti-Mst1 monoclonal antibody (BD Transduction Laboratories) and rabbit polyclonal Mst1 (Abgent). Secondary antibodies were peroxidase-conjugated donkey anti-rabbit or anti-mouse (Jackson ImmunoResearch). Detection of the peroxidase was performed with ECL reagents.
Immunofluorescence staining
Freshly isolated neonatal rat cardiomyocytes were fixed and sequentially incubated with primary antibodies and appropriate fluorescent-labeled secondary antibodies. Images were visualized using an Olympus IX70 epifluorescence microscope as previously described [25].
In Vitro GAPDH phosphorylation assay
To phosphorylate GAPDH in vitro, recombinant GAPDH (Abcam) was incubated with recombinant active Mst1 (Upstate) and [γ-32P]-ATP (PerkinElmer) in 1× kinase assay buffer (40 mM HEPES-NaOH pH 7.4, 20 mM MgCl2, 1 mM DTT, 1 mM ATP, 1 mM Na3VO4, 50 mM NaF, and complete protease inhibitor (Roche) at 30 °C for indicated time points. The reaction was terminated by adding 1/2 volumes of 3× Laemmli sample buffer and incubated at 95 °C for 5 min, then examined by 15% SDS-PAGE and a autoradiography.
Mst1 activity assay
Recombinant active Mst1 (Upstate) or immunoprecipitated Mst1 from HEK293T transfected with Myc-Mst1 cDNA in combination with either empty vector or Flag-GAPDH was incubated for 20 min at 30°C with 4 µg Myelin basic protein (MBP) (Upstate) in 25 µL kinase buffer 40 mmol/L HEPES-NaOH (pH 7.4), 20 mmol/L MgCl2, 1 mmol/L DTT, and 1 µCi [γ-32P]-ATP. Reactions were terminated by the addition of 2× SDS sample buffer, and then loaded to 15% SDS-PAGE and subjected to autoradiography. For Mst1 kinase assay in cardiomyocytes, cell homogenates (400 µg) were immunoprecipitated using anti-Mst1 antibody (BD Transduction Laboratories), and then incubated with 2 µg Histone H2B (Sigma) in 25 µL kinase assay buffer for 20 min at 30°C. Samples were subjected to SDS-PAGE and phosphorylation of histone H2B was detected by immunoblotting with anti-phospho-Histone H2B (Ser14) antibody (Millipore).
Small interfering RNA of GAPDH
Predesigned GAPDH siRNA and control siRNA were purchased from Ambion. Cardiomyocytes were transfected with Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen) with target-specific siRNA (20 nmol/L) and control siRNA (20 nmol/L) in serum-free medium according to the recommendations of the manufacturer.
Construction of adenoviruses
Adenoviruses harboring wild-type Mst1 (Ad-Mst1), dominant-negative Mst1 (Ad-DNMST), and GAPDH were made using AdMax (Microbix) as previously described [21]. Briefly, pBHGloxΔE1,3XCre, including the ΔE1 adenoviral genome, was cotransfected with the pDC shuttle vector containing the gene of interest into AD-293 cells (Stratagene, La Jolla, CA) using FuGene 6 Transfection Reagent (Roche, Indianapolis, IN). AD-293 cell line is a derivative of the commonly used HEK293 cell line, with improved cell adherence and plaque formation properties. The viruses were propagated in AD-293 cells and purified using CsCl2 banding, followed by dialysis against 20 mmol/L Tris-buffered saline with 10% glycerol. Titering was performed on Ad293 cells using Adeno-X Rapid Titer kit (Clontech) according to the instructions of the manufacturer.
Induction of cardiac hypertrophy by chronic infusion of isoproterenol (ISO)
C57BL/6 mice (20–25 g) were anesthetized with a mixture of ketamine (50 mg/kg) and xylazine (2.5 mg/kg) intraperitoneally. The mini-osmotic pumps (Alza corporation, Pa, Alto, CA) set to dispense 0.5 µl/hr for 14 days were filled with PBS or ISO (60 mg/kg/day) and pumps were implanted subcutaneously in the back through a sub-scapular incision, which was then closed using 4.0 silk suture (Ethicon). Mice were followed by echocardiogram prior to pump implantation and then weekly until the end of the 2 week period when mice developed cardiac hypertrophy. This study was reviewed and approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University. Tissue homogenates from normal heart and hypertrophied heart were then subjected to immunoprecipitation by using anti-Mst1 antibody as previously described [25]
Detection of apoptosis
Histone-associated DNA fragments were quantitated by the Cell Death Detection ELISA kit (Roche) [25]. Briefly, the cytoplasmic fractions were added to the 96-well ELISA plates precoated with the antihistone monoclonal antibody and incubated for 90 min at room temperature. After washing, bound nucleosomes were detected by the addition of anti–DNA-peroxidase monoclonal antibody and reacted for 60 min at room temperature. After the addition of substrate, absorbance was read with an ELISA reader at 405 nm. Cardiomyocyte apoptosis measured by using Terminal Transferase-mediated dUTP nick-end labeling (TUNEL) staining was performed using the In Situ Cell Death Detection kit (Roche).
Statistical analyses
Data are expressed as means ± SEM. The statistical significance of differences was assessed by Student's t tests or ANOVA, as appropriate; a value of P<0.05 was considered statistically significant.
Results
Interaction of GAPDH with Mst1
In an effort to identify novel Mst1 binding proteins, a yeast 2-hybrid screening was performed with human dominant negative Mst1 (DN-Mst1) as bait in conjunction with a human heart cDNA library. After screening 2.4×106 clones, we identified 4 positive cDNAs encoding the C-terminal domain (aa 164–335) of GAPDH, suggesting that the C-terminal region of GAPDH may be sufficient to interact with Mst1 in yeast.
To determine whether the interaction between Mst1 and GAPDH occurs in mammalian cells, coimmunoprecipitation experiments were performed in HEK293T cells transfected with GAPDH and Mst1 expression vectors. Immunoprecipitation of FLAG-tagged GAPDH led to coimmunoprecipitation of Myc-tagged Mst1 when both proteins were cotransfected (Figure 1A). As a control, the anti-FLAG antibody did not immunoprecipitate Myc-tagged Mst1 in the absence of FLAG-GAPDH. Similarly, immunoprecipitation of Myc-tagged Mst1 resulted in coimmunoprecipitation of FLAG-tagged GAPDH, whereas the anti-Myc antibody did not immunoprecipitate FLAG-GAPDH in the absence of Myc-Mst1 (Figure 1B). Interestingly, the interaction of GAPDH with Mst1 was further increased by treatment of the cells with the apoptotic agent etoposide (100 M) or TNF- (20 ng/ml) for 6 hrs (Figure 1C). Together, these findings indicate that GAPDH and Mst1 exist in the same complex in mammalian cells both at baseline conditions and during apoptotic stress.
To determine whether there is an endogenous interaction of GAPDH and Mst1 in cardiomyocytes, we performed immunoprecipitation with anti-Mst1 antibody using lysates obtained from neonatal rat ventricular cardiomyocytes (NRVMs). Indeed, GAPDH was co-precipitated with the anti-Mst1 antibody but not with the nonimmune IgG (Figure 2A). The interaction of GAPDH and Mst1 was further examined in the heart. Similarly, GAPDH was only co-immunoprecipitated with the anti-Mst1 antibody, but not with the nonimmune IgG in mouse heart homogenates and this interaction was further increased in the hypertrophic heart (Figure 2B). The results indicate that GAPDH interacts with Mst1 in cardiomyocytes under physiological and pathophysiological conditions.
Interaction domains of GAPDH and Mst1
To further map the interaction domains of GAPDH and Mst1, we performed immunoprecipitation in HEK293 cells cotransfected with different deletion mutants of Mst1 and GAPDH. We first investigated the binding domains of GAPDH in Mst1. Mst1 contains an N-terminal kinase domain (aa 1–325), inhibitory domain (aa 326–294), and a C-terminal dimerization domain (aa 395–487) [3] (Figure 3A). We generated a series of Mst1 deletion mutants subcloned into pCS26MT vector with 6× Myc tag and transfected these mutants into HEK293 cells along with Flag-GAPDH. Lysates from transfected HEK293T cells were immunoprecipitated with anti-myc antibody and analyzed by Western blot analysis using anti-Flag and anti-Myc antibodies. We found that Flag-GAPDH only bound to the N-terminal kinase domain of Mst1 (figure 3B), suggesting that the kinase domain of Mst1 is necessary for interaction with GAPDH.
GAPDH contains two functional domains, namely, the NAD binding domain and the C-terminal catalytic domain [27] (Figure 3C). To map the Mst1-binding domain in GAPDH, Myc-tagged GAPDH mutants were cotransfected into HEK293T cells with Flag-tagged Mst1. Lysates from transfected HEK293T cells were immunoprecipitated with anti-Myc antibody and analyzed by Western blotting analysis using anti-Flag and anti–Myc-antibodies. As shown in Figure 3D, Mst1 interacted only with the entire C-terminal catalytic domain of GAPDH, but not with the NAD binding domain and the deletion mutants derived from the C-terminal catalytic domain. Together, these results further suggest that the C-terminal catalytic domain of GAPDH mediates its interaction with Mst1.
Phosphorylation of GAPDH by Mst1
Since Mst1 is a serine/threonine kinase [1], the interaction of Mst1 with GAPDH prompted us to investigate whether GAPDH is a substrate of Mst1. Therefore purified human GAPDH was incubated with active recombinant Mst1 in the presence of [γ-32P]ATP in an in vitro phosphorylation assay. Indeed, incubation of Mst1 with GAPDH induced a robust phosphorylation of GAPDH in a dose dependent manner (Figure 4A). To determine the kinetics of Mst1-mediated phosphorylation of GAPDH, the time course of Mst1 induced GAPDH phosphorylation was determined in vitro. Indeed, Mst1 phosphorylated GAPDH in a time-dependent manner and reached saturation at 90 min (figure 4B). Strikingly, the activity of either recombinant or endogenous GAPDH was not affected by either incubation with recombinant Mst1 or transduction of cardiomyocytes with adenovirus expressing Mst1 (data not shown).
Activation of Mst1 by GAPDH
To determine whether the interaction of GAPDH with Mst1 has functional consequences in terms of affecting Mst1 activity, we performed an in vitro kinase assay by using either recombinant Mst1 or Mst1 immunoprecipitated from HEK293 cells transfected with the Myc-Mst1 cDNA together with empty vector or Flag-GAPDH plasmid. As expected, incubation of recombinant Mst1 with its known substrate myelin basic protein (MBP) resulted in a robust phosphorylation of MBP, which was not significantly affected in the presence of GAPDH (Figure 5A). Moreover, the phosphorylation activity of Mst1 on GAPDH was about the same as that on the known substrate MBP (Figure 5A). Interestingly, when Mst1 immunoprecipitated from HEK293T cells was used in the kinase assay, cotransfection of GAPDH substantially increased both the Mst1 autophosphorylation and Mst1 mediated MBP phosphorylation by approximately 2-fold (Figure 5B and 5C). These data suggest that other components present in the Mst1 immunocomplexes, but not in the recombinant Mst1, is required for the activation of Mst1 by GAPDH.
Nuclear translocation of Mst1 and GAPDH during cardiomyocyte apoptosis
GAPDH has been shown to induce cell apoptosis through its nuclear translocation [28]. To determine whether GAPDH is involved in cardiomyocyte apoptosis, neonatal rat cardiomyocytes were treated with chelerythrine, a potent inducer of apoptosis [29]. The distribution of GAPDH between the cytoplamic and nuclear fractions was then determined by western blotting analysis. As shown in Figure 6A, in unstimulated cardiac cells, the majority of GAPDH is located in the cytoplasm. However, treatment of cardiomyocytes with chelerythrine for either 1 hr or 2 hr substantially increased the amount of GAPDH in the nuclear fraction. To further substantiate the role of Mst1 and GAPDH in cardiomyocyte apoptosis, we performed immunofluorescence staining to determine the intracellular localization of GAPDH and Mst1 in cardiomyocytes. As shown in Figure 6B, the majority of GAPDH and Mst1 is colocalized in the cytoplasm in unstimulated cardiac cells. However, chelerythrine treatment led to a marked translocation and co-localization of both GAPDH and Mst1 in the nucleus. The kinase activity of Mst1 is not required for the nuclear translocation of GAPDH, since transduction of cardiomyocytes with adenovirus bearing either wild-type Mst1 (Ad-Mst1, MOI = 30) or dominant negative Mst1 (Ad-DNMST, MOI = 30) had no effect on the nuclear translocation of GAPDH induced by chelerythrine stimulation (Figure 6C). Furthermore, the interaction of GAPDH with Mst1 was further increased in cardiomyocytes in response to chelerythrine treatment, as demonstrated in the co-immunoprecipitation experiment using anti-Mst1 antibody (Figure 6D). Together, these results suggest that translocation of GAPDH and Mst1 into nucleus may play an essential role in Mst1 activation and cardiomyocyte apoptosis.
GAPDH enhances Mst1 induced cardiomyocyte apoptosis
Because Mst1 has been characterized to induce cardiomyocyte apoptosis [23], [24], we investigated whether GAPDH can affect cell apoptosis via its stimulatory effect on Mst1 in cardiac myocytes. Indeed, transduction of cardiomyocytes with adenovirus bearing GAPDH (Ad-GAPDH, MOI = 30) resulted in an increased expression of GAPDH (Figure 7A). As expected, transduction of cardiomyocytes with Ad-Mst1 (MOI = 30) significantly induced apoptosis as compared with cells transduced with Ad-lacZ (MOI = 30), as determined by the Cell Death ELISA (Roche) (Figure 7B). However, transduction of cardiomyocytes with Ad-GAPDH (MOI = 30) alone barely affected the basal levels of cell apoptosis, but substantially enhanced the Mst1 induced apoptosis. In addition, overexpression of GAPDH markedly augmented the cardiomyocyte apoptosis in response to chelerythrine stimulation, which was significantly inhibited by overexpression of DN-Mst1 (Figure 7C). These findings suggest that the interaction of GAPDH with Mst1 may be functionally important in terms of regulating Mst1-mediated cardiomyocyte apoptosis.
Knockdown of GAPDH attenuates Mst1 activation and cardiomyocyte apoptosis
To further investigate the role of GAPDH in the regulation of Mst1 mediated cardiomyocytes, we used siRNA to knockdown the expression of GAPDH. Transfection of GAPDH siRNA (siGAPDH) reduced GAPDH expression by ∼80% in cardiomyocytes, as determined by both qRT-PCR (Figure 8A) and western blot analysis (Figure 8B). Knockdown of GAPDH expression was found to markedly attenuate Mst1 activity in response to chelerythrine treatment, as compared with that in cells transfected with control siRNA (siCTL) (Figure 8C). Moreover, knockdown of GAPDH expression markedly inhibited the cardiomyocyte apoptosis in response to chelerythrine, as determined by TUNEL staining (Figure 8D). However, transduction of cardiomyocytes with Ad-Mst1 (MOI = 50) fully restored the cardiomyocyte apoptosis induced by chelerythrine stimulation in cardiomyocytes transfected with GAPDH siRNA (Figure 8D). Importantly, knockdown of GAPDH also markedly inhibited hypoxia/reoxygenation induced Mst1 activation (Figure 9A) and cardiomyocyte apoptosis (Figure 9B). Collectively, these findings further indicate that GAPDH is a positive regulator of Mst1 activation in cardiomyocyte apoptosis.
Discussion
Using the yeast 2-hybrid system and Mst1 as bait, we isolated several GAPDH cDNAs from a human heart cDNA library. The interaction of GAPDH with wild-type Mst1 was further supported by coimmunoprecipitation studies showing that in both cotransfected HEK293T cells and cardiomyocytes, GAPDH specifically interacts with Mst1. The interaction between GAPDH and Mst1 requires the kinase domain of Mst1 and it seems that the C-terminal catalytic domain of GAPDH mediates the binding of Mst1 in GAPDH. Interestingly, GAPDH is phosphorylated by Mst1 to a comparable extent as its known substrate MBP, suggesting that GAPDH is a good substrate of Mst1 at least in vitro. Furthermore, the functional consequence of this interaction was demonstrated by the ability of GAPDH to enhance Mst1 activity and Mst1-mediated apoptotic effects in cardiomyocytes. Indeed, inhibition of GAPDH expression attenuates the Mst1 activation and the Mst1 induced cardiomyocyte apoptosis in response to chelerythrine. These results suggest that the regulation of Mst1 activity by GAPDH may be an important determinant of cell survival in the heart.
GAPDH is a key enzyme in the glycolytic pathway, which catalyzes the conversion of glyceraldehyde-3-phosphate (G3P) to 1,3-biphosphoglycerate in the presence of NAD+ and inorganic phosphate [28]. Recently, accumulating evidence suggests that in addition to its canonical role in the glycolytic pathway, GAPDH functions as a key component in the regulation of many fundamental cellular functions [28]. Particularly, its roles in the nucleus and in the regulation of cell apoptosis have attracted significant attention [30], [31]. Indeed, increased expression and nuclear translocation of GAPDH has been implicated in the cell apoptosis in several cell types [30], [32], [33]. However, at this time, the molecular mechanism underlying the cell apoptosis triggered by GAPDH nuclear translocation remains elusive. Recently, nitrosative stress conditions have been shown to induce nitrosylation of GAPDH and its interaction with the ubiquitin ligase Siah1, which translocates GAPDH to the nucleus [30]. In the nucleus, GAPDH stabilizes the rapidly turning Siah1 complex, leading to ubiquitination and subsequent degradation of selected target proteins, thereby affecting apoptosis [30]. In addition, GAPDH has been shown to facilitate apoptosis when localized to mitochondria, where it induces the pro-apoptotic mitochondrial membrane permeabilization and the release of pro-apoptotic cytochome c [34]. The functional role of GAPDH in cardiomyocyte apoptosis has begun to be explored. For instance, the increased GAPDH gylcolytic activity induced by phenylephrine treatment has recently been shown to protect the cardiomyocytes from the starvation induced apoptosis [35] and this appears to disagree with the conclusion of the present study. The cause of this discrepancy may be due to the different external stimuli used for inducing apoptosis, since increased GAPDH activity can generate more ATP, which can counteract the decreased ATP levels during the starvation induced apoptosis. Interestingly, a recent report demonstrated that during nitric oxide (NO)-induced cardiomyocyte apoptosis, GAPDH is translocated to the nucleus of cardiomyocytes and overexpression of glutaredoxin protects cardiomyocytes against NO induced apoptosis through suppressing the translocation of GAPDH [36]. In the present study, our data demonstrated that GAPDH specifically binds to Mst1 and translocates to the nucleus during cardiomyocyte apoptosis. Inhibition of GAPDH attenuates Mst1 activation and Mst1 mediated cardiomyocyte apoptosis. Thus, our findings identified Mst1 as a novel downstream target of GAPDH in cardiomyocyte apoptosis.
The Mst1 signaling pathway plays an essential role in cell apoptosis [2]. Intact Mst1 is localized predominantly in the cytoplasm, however, in response to a variety of apoptotic stimuli, Mst1 is cleaved by caspases to produce the N-terminal constitutively active kinase domain and this cleavage markedly increases Mst1 kinase activity and translocates the cleaved Mst1 to the nucleus [4]–[6]. In the present study, our results demonstrated that both GAPDH and Mst1 translocated to the nucleus and strongly colocalized in the nucleus in response to chelerythrine. The interaction of GAPDH with Mst1 in the nucleus could be critical for the execution of cell apoptosis, since GAPDH can further augments Mst1 activity in the nucleus, thereby potentiating the Mst1 induced apoptosis. In addition, the interaction of Mst1 with GAPDH could further lead to GAPDH phosphorylation, therefore affecting its interaction with other downstream targets such as Siah1 and p300 in the nucleus [30], [31], thereby influencing cell apoptosis. Although the function of the Mst1 mediated GAPDH phosphorylation remains unknown, it would be very interesting to investigate whether Mst1 mediated GAPDH phosphorylation affects its other functions in the nucleus, such as mediating RNA nuclear export, gene transcription, mRNA stability, and telomere protection [37], [38].
The mechanism by which GAPDH activates Mst1 is not known, but certainly involves other components in Mst1 immunocomplexes, as such an increased Mst1 activity by GAPDH was only observed with immunoprecipitated Mst1 from HEK293 cells transfected with Mst1 cDNA. Indeed, the Mst1 kinase signaling cascade is tightly regulated by protein–protein interactions. Several proteins, including Rassf1, hWW45 [17], [19], PHLPP1 [20], and Death-associated Protein 4 (DAP4) [5], have been shown to interact with Mst1, thereby influencing the activities of MST1/2 kinases in mammalian cells. In this regard, it is attempting to speculate that the interaction of GAPDH with Mst1 may cause a conformational change of Mst1, thus affecting the formation of the Mst1/Hippo signaling complex with other proteins, such as Rassf1, hWW45, and Lats, which have recently been shown to play essential roles in the regulation of cardiomyocyte apoptosis and heart failure [39], [40]. These studies are ongoing.
In summary, we have found that GAPDH interacts with Mst1 kinase in cardiomyocytes. This interaction is specific and leads to a functional increase in Mst1 activity and Mst1 mediated cardiomyocyte apoptosis. These findings suggest that the GAPDH/Mst1 pathway may be an important therapeutic target for inhibiting myocardial apoptosis in ischemia-reperfusion injury and heart failure.
Funding Statement
This work was supported by the National Natural Science Foundation of China [grant number 381170114] and the National Institutes of Health [grant number R01HL103869] (to JS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Chan SW, Lim CJ, Chen L, Chong YF, Huang C, et al. (2011) The hippo pathway in biological control and cancer development, J. Cell. Physiol 226: 928–939. [DOI] [PubMed] [Google Scholar]
- 2. Avruch J, Zhou D, Fitamant J, Bardeesy N (2011) Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br. J. Cancer 104: 24–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Creasy CL, Ambrose DM, Chernoff J (1996) The Ste20-like protein kinase, Mst1, dimerizes and contains an inhibitory domain. J. Biol. Chem 271: 21049–21053. [DOI] [PubMed] [Google Scholar]
- 4. Ura S, Masuyama N, Graves JD, Gotoh Y (2001) Caspase cleavage of MST1 promotes nuclear translocation and chromatin condensation, Proc. Natl. Acad. Sci. U S A 98: 10148–10153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Lin Y, Khokhlatchev A, Figeys D, Avruch J (2002) Death-associated protein 4 binds MST1 and augments MST1-induced apoptosis. J. Biol. Chem 277: 47991–48001. [DOI] [PubMed] [Google Scholar]
- 6. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, et al. (2003) Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 113: 507–517. [DOI] [PubMed] [Google Scholar]
- 7. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, et al. (2006) A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 125: 987–1001. [DOI] [PubMed] [Google Scholar]
- 8. Yuan Z, Lehtinen MK, Merlo P, Villen J, Gygi S, et al. (2009) Regulation of neuronal cell death by MST1-FOXO1 signaling. J. Biol. Chem 284: 11285–11292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Jang SW, Yang SJ, Srinivasan S, Ye K (2007) Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. J. Biol.Chem 282: 30836–30844. [DOI] [PubMed] [Google Scholar]
- 10. Huang J, Wu S, Barrera J, Matthews K, Pan D (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122: 421–434. [DOI] [PubMed] [Google Scholar]
- 11. Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, et al. (2005) The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 24: 2076–2086. [DOI] [PubMed] [Google Scholar]
- 12. Bi W, Xiao L, Jia Y, Wu J, Xie Q, et al. (2010) c-Jun N-terminal kinase enhances MST1-mediated pro-apoptotic signaling through phosphorylation at serine 82. J. Biol. Chem 285: 6259–6264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. You B, Yan G, Zhang Z, Yan L, Li J, et al. (2009) Phosphorylation of cardiac troponin I by mammalian sterile 20-like kinase 1. Biochem. J 418: 93–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Graves JD, Draves KE, Gotoh Y, Krebs EG, Clark EA (2001) Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis. J. Biol. Chem 276: 14909–14915. [DOI] [PubMed] [Google Scholar]
- 15. Glantschnig H, Roda GA, Reszka AA (2002) Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation. J. Biol. Chem 277: 42987–42996. [DOI] [PubMed] [Google Scholar]
- 16. Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J (2004) Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem. J. 381: 453–462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Guo C, Tommasi S, Liu L, Yee JK, Dammann R, et al. (2007) RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr. Biol 17: 700–705. [DOI] [PubMed] [Google Scholar]
- 18. Cooper WN, Hesson LB, Matallanas D, Dallol A, von Kriegsheim A, et al. (2009) RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 28: 2988–2998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Zeng Q, Hong W (2008) The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer. Cell 13: 188–192. [DOI] [PubMed] [Google Scholar]
- 20. Qiao M, Wang Y, Xu X, Lu J, Dong Y, et al. (2010) Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol. Cell 38: 512– 523. [DOI] [PubMed] [Google Scholar]
- 21. Ren A, Yan G, You B, Sun J (2008) Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer. Res 68: 2266–2274. [DOI] [PubMed] [Google Scholar]
- 22. Guo C, Zhang X, Pfeifer GP (2011) The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J. Biol. Chem 286: 6253–6261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Yamamoto S, Yang G, Zablocki D, Liu J, Hong C, et al. (2003) Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J. Clin. Invest 111: 1463–1474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Odashima M, Usui S, Takagi H, Hong C, Liu J, et al. (2007) Inhibition of endogenous Mst1 prevents apoptosis and cardiac dysfunction without affecting cardiac hypertrophy after myocardial infarction. Circ. Res 100: 1344–1352. [DOI] [PubMed] [Google Scholar]
- 25. Sun J, Yan G, Ren A, You B, Liao JK (2006) FHL2/SLIM3 decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1. Circ. Res 99: 468–476. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Caporali A, Sala-Newby GB, Meloni M, Graiani G, Pani E, et al. (2008) Identification of the prosurvival activity of nerve growth factor on cardiac myocytes. Cell Death and Differentiation 15: 299–311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Nagy E, Henics T, Eckert M, Miseta A, Lightowlers RN, et al. (2000) Identification of the NAD(+)-binding fold of glyceraldehyde-3-phosphate dehydrogenase as a novel RNA-binding domain, Biochem. Biophys. Res. Commun 275: 253–260. [DOI] [PubMed] [Google Scholar]
- 28. Nicholls C, Li H, Liu JP (2012) GAPDH: A common enzyme with uncommon functions, Clin. Exp. Pharmacol. Physiol 39: 674–9. [DOI] [PubMed] [Google Scholar]
- 29. Yamamoto S, Seta K, Morisco C, Vatner SF, Sadoshima J (2001) Chelerythrine rapidly induces apoptosis through generation of reactive oxygen species in cardiac myocytes. J Mol. Cell. Cardiol 33: 1829–1848. [DOI] [PubMed] [Google Scholar]
- 30. Hara MR, Agrawal N, Kim SF, Cascio MB, Fujimuro M, et al. (2005) S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat. Cell. Biol 7: 665–674. [DOI] [PubMed] [Google Scholar]
- 31. Sen N, Hara MR, Kornberg MD, Cascio MB, Bae BI, et al. (2008) Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat. Cell. Biol 10: 866–873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Madsen-Bouterse S, Mohammad G, Kowluru RA (2010) Glyceraldehyde-3-phosphate dehydrogenase in retinal microvasculature: implications for the development and progression of diabetic retinopathy, Invest. Ophthalmol. Vis. Sci 51: 1765–1772. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Tajima H, Tsuchiya K, Yamada M, Kondo K, Katsube N, et al. (1999) Over-expression of GAPDH induces apoptosis in COS-7 cells transfected with cloned GAPDH cDNAs. Neuroreport 10: 2029–2033. [DOI] [PubMed] [Google Scholar]
- 34. Tarze A, Deniaud A, Le Bras M, Maillier E, Molle D, et al. (2007) GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene 26: 2606–2620. [DOI] [PubMed] [Google Scholar]
- 35. Yao LL, Wang YG, Liu XJ, Zhou Y, Li N, et al. (2012) Phenylephrine protects cardiomyocytes from starvation-induced apoptosis by increasing glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity. J. Cell. Physiol 227: 3518–27. [DOI] [PubMed] [Google Scholar]
- 36. Inadomi C, Murata H, Ihara Y, Goto S, Urata Y, et al. (2012) Overexpression of glutaredoxin protects cardiomyocytes against nitric oxide-induced apoptosis with suppressing the S-nitrosylation of proteins and nuclear translocation of GAPDH, Biochem. Biophys. Res. Commun 425: 656–61. [DOI] [PubMed] [Google Scholar]
- 37. Singh R, Green MR (1993) Sequence-specific binding of transfer RNA by glyceraldehyde-3-phosphate dehydrogenase. Science 259: 365–368. [DOI] [PubMed] [Google Scholar]
- 38. Sundararaj KP, Wood RE, Ponnusamy S, Salas AM, Szulc Z, et al. (2004) Rapid shortening of telomere length in response to ceramide involves the inhibition of telomere binding activity of nuclear glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem 279: 6152–6162. [DOI] [PubMed] [Google Scholar]
- 39. Matsui Y, Nakano N, Shao D, Gao S, Luo W, et al. (2008) Lats2 is a negative regulator of myocyte size in the heart. Circ. Res 103: 1309–1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Del Re DP, Matsuda T, Zhai P, Gao S, Clark GJ, et al. (2010) Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice. J. Clin. Invest 120: 3555–3567. [DOI] [PMC free article] [PubMed] [Google Scholar]